They found that low expression of GBP2 was associated with weakened immune responses and poor prognosis of colorectal cancer patients, which suggested that GBP2 could serve as a potential immunotherapy target for colorectal cancer [14]. This evidence concerns the gene GBP2 and colorectal cancer.